Skip to main content

Sitagliptin improves renal function in diabetic nephropathy in male Sprague Dawley rats through upregulating heme oxygenase-1 expression

Endocrine volume 63, pages 70–78 (2019)Cite this article

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Purpose

Oxidative stress is an important mechanism for diabetic nephropathy. Studies showed that hemo oxygenase-1 (HO-1) expression in renal tissue of patients with diabetic nephropathy has upregulated, while the HO-1 can protect the body through anti-oxidative stress. The study aimed to preliminarily explore the molecular mechanism by observing the effect of Sitagliptin on HO-1 expression in renal tissue of rats with diabetic nephropathy.

Methods

The diabetic nephropathy rat model was established by STZ injection followed by intraperitoneal injection of sitagliptin with different concentrations. The mRNA expressions of HO-1 were detected by real-time PCR and Western blot and HO-1 enzyme activity change was detected by colorimetry. Human renal mesangial cell (HRMC) were cultured in vitro with high glucose concentration (30 μmol/L), phosphatidylinositol-3-kinase (PI3K) level and nuclear factor erythroid-2-related factor (Nrf2) content in cytoplasm and cell nucleus were observed before and after treatment with sitagliptin, as well as the action of in meditating HO-1 expression.

Results

HO-1 mRNA, protein level, and HO-1 enzyme activity in renal tissue of rats with diabetic nephropathy were significantly increased after treatment with sitagliptin (P < 0.05). As comparison, the 24 h urinary microalbumin, creatinine, and boold urea nitrogen were all decreased after treatment of sitagliptin (P < 0.05). Similar results were observed after CoPP (an agonist of HO-1) treatment (P < 0.05). In contrast, ZnPP, an inhibitor of HO-1, significantly abrogated the inhibitory effect of sitagliptin (P < 0.05). Phosphorylation of PI3K and Nrf2 nuclear translocation under high-glucose concentration condition was induced by sitagliptin in HRMC. HO-1 expression was suppressed by pretreating HRMC with PI3K inhibitor or RNA interference.

Conclusions

Sitagliptin may induce HO-1 expression via activation of PI3K and Nrf2 in rats with diabetic nephropathy; HO-1 can improve the oxidative stress of diabetic nephropathy, eventually protect from diabetic nephropathy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

References

  1. N.R. Robles, J. Villa, R.H. Gallego, Non-proteinuric diabetic nephropathy. J. Clin. Med. 4(9), 1761–1773 (2015)

    Article  CAS  Google Scholar 

  2. H. Wang, K. Cui, K. Xu, S. Xu, Association between plasma homocysteine andprogression of early nephropathy in type 2 diabetic patients. Int. J. Clin. Exp. Med. 8(7), 11174–11180 (2015)

    CAS  PubMed  PubMed Central  Google Scholar 

  3. A. Tagawa, M. Yasuda, S. Kume, K. Yamahara, J. Nakazawa, M. Chin-Kanasaki, H. Araki, S.I. Araki, D. Koya, K. Asanuma, E.H. Kim, M. Haneda, N. Kajiwara, K. Hayashi, H. Ohashi, S. Ugi, H. Maegawa, T. Uzu, Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy. Diabetes 65(3), 755–767 (2016)

    Article  CAS  Google Scholar 

  4. M.W. Mashitah, N. Azizah, N. Samsu, M.R. Indra, M. Bilal, M.V. Yunisa, AD. Arisanti, Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice. Diabetes Metab. Syndr. Obes. 8, 347–355 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. K. Schror, B.H. Rauch, Aspirin and lipid mediators in the cardiovascular system. Prostaglandins Other Lipid Mediat. 121(Pt A), 17–23 (2015)

    Article  Google Scholar 

  6. M. Kamiyama, M. Urushihara, T. Morikawa, Y. Konishi, M. Imanishi, A. Nishiyama, H. Kobori, Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy. Int. J. Mol. Sci. 14(11), 23045–23062 (2013)

    Article  Google Scholar 

  7. A. Zarjou, A. Agarwal, Heme oxygenase-1 as a target for TGF-beta in kidney disease. Semin. Nephrol. 32(3), 277–286 (2012)

    Article  CAS  Google Scholar 

  8. E.O. Ptilovanciv, G.S. Fernandes, L.C. Teixeira, L.A. Reis, E.A. Pessoa, M.B. Convento, M.J. Simoes, G.A. Albertoni, N. Schor, F.T. Borges, Heme oxygenase 1 improves glucoses metabolism and kidney histological alterations in diabetic rats. Diabetol. Metab. Syndr. 5(1), 3–10 (2013)

    Article  CAS  Google Scholar 

  9. J. Skov, Effects of GLP-1 in the kidney. Rev. Endocr. Metab. Disord. 15(3), 197–207 (2014)

    Article  CAS  Google Scholar 

  10. H. Mori, Y. Okada, T. Arao, Y. Tanaka, Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J. Diabetes Investig. 5(3), 313–319 (2014)

    Article  CAS  Google Scholar 

  11. Y. Ishibashi, T. Matsui, M. Takeuchi, S. Yamagishi, Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem. Biophys. Res. Commun. 391(3), 1405–1408 (2010)

    Article  CAS  Google Scholar 

  12. Chen Yang, Wang Jianping, Jiang Aihua, Fu Ting, Deng Shanshan, The expression changes of the of 8-hydroxyl guanosine and superoxide dismutase in the kidney of diabetic rats and its effect of sitagliptin. Chin. J. Diabetes 23(1), 75–78 (2015)

    CAS  Google Scholar 

  13. A. Paine, B. Eiz-Vesper, R. Blasczyk, S. Immenschuh, Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem. Pharmacol. 80(12), 1895–1903 (2010)

    Article  CAS  Google Scholar 

  14. G. Czibik, G. Derumeaux, D. Sawaki, G. Valen, R. Motterlini, Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology. Basic Res. Cardiol. 109(6), 450 (2014)

    Article  Google Scholar 

  15. S.S. Kim, J. Lim, Y. Bang, J. Gal, S.U. Lee, Y.C. Cho, G. Yoon, B.Y. Kang, S.H. Cheon, H.J. Choi, Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease. J. Nutr. Biochem. 23(10), 1314–1323 (2012)

    Article  CAS  Google Scholar 

  16. H. Zhao, M. Ozen, R.J. Wong, D.K. Stevenson, Heme oxygenase-1 in pregnancy and cancer: similarities in cellular invasion, cytoprotection, angiogenesis, and immunomodulation. Front. Pharmacol. 5, 295 (2014)

    Article  Google Scholar 

  17. J. Fang, T. Seki, H. Maeda, Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 61(4), 290–302 (2009)

    Article  CAS  Google Scholar 

  18. R.N. Frank, R.H. Amin, J.E. Puklin, Antioxidant enzymes in the macular retinal pigment epithelium of eyes with neovascular age-related macular degeneration. Am. J. Ophthalmol. 127(6), 694–709 (1999)

    Article  CAS  Google Scholar 

  19. C. Dong, H. Zheng, S. Huang, N. You, J. Xu, X. Ye, Q. Zhu, Y. Feng, Q. You, H. Miao, D. Ding, Y. Lu, Heme oxygenase-1 enhances autophagy in podocytes as a protective mechanism against high glucose-induced apoptosis. Exp. Cell Res. 337(2), 146–159 (2015)

    Article  CAS  Google Scholar 

  20. S. Koyasu, The role of PI3K in immune cells. Nat. Immunol. 4(4), 313–319 (2003)

    Article  CAS  Google Scholar 

  21. G.E. Mann, J. Niehueser-Saran, A. Watson, L. Gao, T. Ishii, P. de Winter, R.C. Siow, Nrf2/ARE regulated antioxidant gene expression in endothelial and smooth muscle cells in oxidative stress: implications for atherosclerosis and preeclampsia. Sheng Li Xue Bao 59(2), 117–127 (2007)

    CAS  PubMed  Google Scholar 

  22. A.S. Jimenez-Osorio, S. Gonzalez-Reyes, J. Pedraza-Chaverri, Natural Nrf2 activators in diabetes. Clin. Chim. Acta 448, 182–192 (2015)

    Article  CAS  Google Scholar 

  23. Y.S. Oh, H.S. Jun, Effects of Glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. Int. J. Mol. Sci. 19(1), 26 (2018)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, The Second Affiliated Hospital of University of South China, Hengyang, 421001, Hunan, China

    Jianping Wang, Lan Hu, Yang Chen, Ting Fu, Tao Jiang & Aihua Jiang

  2. Department of Endocrinology, The First people’s Hospital of Xiangtan City, Xiangtan, 411100, Hunan, China

    Lan Hu

  3. University of South China, Hengyang, 421001, Hunan, China

    Xiaoxing You

Authors
  1. Jianping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ting Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tao Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aihua Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoxing You
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianping Wang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Hu, L., Chen, Y. et al. Sitagliptin improves renal function in diabetic nephropathy in male Sprague Dawley rats through upregulating heme oxygenase-1 expression. Endocrine 63, 70–78 (2019). https://doi.org/10.1007/s12020-018-1721-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-018-1721-2

Keywords

  • Sitagliptin
  • Heme oxygenase-1
  • Diabetic nephropathy
  • Phosphoinositide 3-kinase
  • Nuclear factor erythroid-2 related factor (Nrf2)
  • Phosphatidylinositol-3-kinase (PI3K)